More recently, the US Food and Drug Administration (FDA) applied a ”black box” warning to all antidepressant drugs labelling, but fell short of restricting the use of any individual drug. This was done after an FDA commissioned re-analysis of safety data from all trials of the newer antidepressants demonstrated increased risk of suicidality (definitive suicidal behaviour/ ideation) and increased risk of treatment-emergent hostility or agitation in those treated with the active drug compared to placebo.